Table 3 The role of STAT3 signaling in developing drug resistance in HCC

STAT3/Mcl-1

Inhibition of the STAT3/Mcl-1 axis promotes tumor cell sensitivity to 5-fluorouracil

[240]

DANCR/IL-6/STAT3

DANCR promotes IL-6 levels to induce STAT3 signaling in the development of sorafenib resistance

[241]

Gankyrin/STAT3

Gankyrin stimulates STAT3 signaling in mediating sorafenib resistance in tumor cells

[242]

STAT3/PTTG1

Falcarindiol suppresses STAT3/PTTG1 axis in increasing cisplatin sensitivity of tumor cells

[243]

STAT3

Suppression of STAT3 signaling by YC-1 is important in enhancing drug sensitivity of tumor cells

[244]

STAT3

Inhibition of STAT3 signaling by NSC 74,859 is significant in enhancing the anticancer activity of cetuximab

[245]

MAEL/Akt/STAT3

MAEL stimulates the Akt/STAT3 axis to increase stemness and mediate sorafenib resistance

[246]

miR-589-5p/STAT3

miR-589-5p reduces the expression levels of SOCS2, SOCS5, PTPN1, and PTPN11 to induce STAT3 signaling in doxorubicin resistance

[247]

Let-7a/STAT3

Let-7a reduces STAT3 expression and increases the sensitivity of HCC cells to cetuximab

[248]

RhoE/ROCK2/IL-6/STAT3

Downregulation of RhoE leads to upregulation of ROCK2 to induce STAT3 signaling in developing chemoresistance

[249]

HOTAIR/STAT3/ABCB1

HOTAIR induces STAT3 signaling to increase ABCB1 expression in the development of cisplatin resistance

[250]

MAPK/ERK/STAT3

Metformin promotes the cytotoxicity of sorafenib by suppressing the MAPK/ERK/STAT3 axis

[251]